FDA Advisory Panel Supports Moderna's mRNA Flu Vaccine Despite Earlier Controversies
← Back
Life

FDA Advisory Panel Supports Moderna's mRNA Flu Vaccine Despite Earlier Controversies

An FDA advisory panel has endorsed Moderna's seasonal mRNA flu vaccine, which had previously been embroiled in controversy earlier this year.

Editorial Staff1 min

A panel of advisers to the FDA has recently given its backing to a seasonal mRNA flu vaccine created by Moderna.

This endorsement comes after the vaccine faced scrutiny and controversy earlier in the year.

The decision reflects the panel's assessment of the vaccine's potential benefits amidst the ongoing discussions about its safety and efficacy.

Updates

Update at 20:26 UTC on 2026-06-18

STAT reported A panel of advisers to FDA gave its endorsement to a seasonal mRNA flu vaccine that was developed by Moderna and that earlier this year became the subject of controversy.

Sources: STAT